Ranbaxy

India-based drug maker Ranbaxy Laboratories has agreed to pay $39.75m to settle litigation about its participation in Texas Medicaid, a US health care programme for people with low incomes.

The company was investigated by the US state of Texas, for misrepresenting the drug price data, at the start of the year.

Ranbaxy said it will make the payments in tranches throughout August 2015.

According to Ranbaxy, the issue related to the manner the company historically reported pricing data to Texas Medicaid for its drugs.

In May, the company said it made a provision of $38.57m in its first quarter results for ‘certain settlements done with the government authorities’ in the US, reported Reuters.

In September, the company said US federal authorities gathered information on how it reported pricing data for certain products eligible for reimbursement under Medicaid.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company, which will be acquired by Sun Pharmaceutical Industries, said it ‘believes it fully complied with all the relevant laws’.

In 2013, the drug maker reached a settlement agreement with the US Department of Justice to pay $500m in civil and criminal fines over drug safety violations.


Image: Ranbaxy has settled the Texas Medicaid litigation by agreeing to pay a sum of $39.75m. Photo: courtesy of pixtawan/FreeDigitalPhotos.net.